1
|
Herman R, Sładek M, Pieczarkowski S, Dumnicka P, Fyderek K. Is mean platelet volume a good predictor of sustained response to one year infliximab therapy in pediatric patients with Crohn's disease? Folia Med Cracov 2017; 57:63-71. [PMID: 29121038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Over the past years, there is a growing number of newly diagnosed pediatric patients with Crohn's disease (CD). Severe course of CD often requires biological treatment with Infliximab (IFX). Loss of response to biological treatment is a major problem. Mean platelet volume (MPV) was reported as a good marker of sustained response to IFX therapy in adults. This study is to determine whether MPV measured prior to IFX therapy and a er its third dose can be used as a predictive marker of sustained response to biological therapy in children with severe course of CD. 43 pediatric patients with CD who underwent IFX therapy were enrolled into this study. The clinical response was evaluated after the third dose and after one year of IFX treatment (sustained response). The MPV values at baseline and week 14 were compared to the patients with good response to IFX to those with loss of the response. During 52-week IFX therapy, 2 out of 43 patients enrolled in the study did not achieve primary response a er the third dose, another 18 children lost their response to the above therapy a er one year. There was no significant association between baseline and 14th week values of MPV between patients with the sustained response to those with loss of response. In opposite to adult patients, MPV cannot be regarded as predictive factor of sustained response to IFX treatment in pediatric patients.
Collapse
Affiliation(s)
- Roma Herman
- Department of Pediatrics, Gastroenterology and Nutrition Jagiellonian University Medical College, Wielicka 265, Kraków, Poland.
| | | | | | | | | |
Collapse
|
2
|
Iwańczak BM, Ryżko J, Jankowski P, Sładek M, Wasilewska A, Szczepanik M, Sienkiewicz E, Szaflarska-Popławska A, Więcek S, Czaja-Bulsa G, Korczowski B, Maślana J, Iwańczak F, Kacperska M. Evaluation of the infliximab therapy of severe form of pediatric Crohn's disease in Poland: Retrospective, multicenter studies. ADV CLIN EXP MED 2017; 26:51-56. [PMID: 28397432 DOI: 10.17219/acem/35802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
BACKGROUND Registration of infliximab in Poland has increased chances to induce clinical remission and mucosal healing in the severe form of pediatric Crohn's disease. OBJECTIVES The aim of this retrospective study was to assess the results and safety of infliximab therapy in the severe form of pediatric Crohn's disease. MATERIAL AND METHODS The study included 153 children with severe form of non-fistulizing Crohn's disease treated with infliximab. The clinical activity of Crohn's disease was assessed according to PCDAI scale, endoscopic scoring was graded according to SES-CD, body mass was measured with body mass index (BMI). Infliximab was administered at the dose 5 mg/kg body mass in the 0.2 and 6th week, and then, after clinical response, every 8 for the period of 12 months. RESULTS One hundred thirty-six children (88.89%) achieved clinical response after induction therapy and 75.21% of children after the maintenance therapy. 39.68% of children achieved remission as graded with endoscopic scoring SES-CD. There was a statistically significant increase in body weight following the treatment. Side effects such as anaphylaxis, rash, and the activation of EBV infection appeared in 9 children at the time of infliximab injection. In other children the drug was well tolerated. CONCLUSIONS Induction and maintenance therapy with infliximab resulted in clinical remission of Crohn's disease in 75.21% of children, and in the intestinal mucosa healing in 39.68% of children.
Collapse
Affiliation(s)
- Barbara M Iwańczak
- Department and Clinic of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland
| | - Józef Ryżko
- Children's Memorial Health Institute, Warsaw, Poland
| | | | - Małgorzata Sładek
- Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University School of Medicine, Kraków, Poland
| | - Agata Wasilewska
- Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University School of Medicine, Kraków, Poland
| | - Mariusz Szczepanik
- Department of Pediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Science, Poland
| | - Edyta Sienkiewicz
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Poland
| | - Anna Szaflarska-Popławska
- Department of Pediatrics, Allergology and Gastroenterology, Collegium Medicum, Nicolaus Copernicus University of Toruń, Bydgoszcz, Poland
| | - Sabina Więcek
- Department of Pediatrics, Medical University of Silesia, Gastroenterology Unit, Upper Silesian Child Health Care Center, Katowice, Poland
| | - Grażyna Czaja-Bulsa
- Pediatric Nursery Unit of Pomeranian Medical University, Division of Pediatrics, Gastroenterology and Reumatology of Zdroje Hospital, Szczecin, Poland
| | - Bartosz Korczowski
- Department of Pediatrics, State Hospital, Medical College, Rzeszów, Poland
| | | | - Franciszek Iwańczak
- Department and Clinic of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland
| | - Magdalena Kacperska
- Pediatric Nursery Unit of Pomeranian Medical University, Division of Pediatrics, Gastroenterology and Reumatology of Zdroje Hospital, Szczecin, Poland
| |
Collapse
|
3
|
Iwańczak BM, Ryżko J, Jankowski P, Sładek M, Wasilewska A, Szczepanik M, Sienkiewicz E, Szaflarska-Popławska A, Więcek S, Kwiecień J, Korczowski B, Maślana J. Induction and Maintenance Infliximab Therapy for the Treatment of Crohn's Disease with Perianal Fistulas in Children: Retrospective, Multicenter Study. ADV CLIN EXP MED 2016; 25:523-30. [PMID: 27629741 DOI: 10.17219/acem/36417] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Revised: 02/20/2015] [Accepted: 03/23/2015] [Indexed: 11/24/2022]
Abstract
BACKGROUND Infliximab is a biological drug used for the treatment of Crohn's disease in children. OBJECTIVES The aim of this retrospective study was the estimation of effectiveness and safety of infliximab in the treatment of Crohn's disease with perianal fistulas in children. MATERIAL AND METHODS Analysis comprised 50 children with Crohn's disease with perianal fistulas aged 9 to 18 years (16 girls and 34 boys) who failed to respond to conventional therapy. The children were divided into two groups: the first group contained 23 children with simple fistulas and the second - 27 children with complex fistulas. All children were treated with infliximab, administered in the dose of 5 mg per kilogram of the body mass. In the induction phase infliximab was administered at weeks 0, 2 and 6 and after clinical response in maintenance phase the drug was administered every 8 weeks; together for 12 months. RESULTS In 76% of children after induction therapy with infliximab and in 71.87% after maintenance therapy the complete closure of fistula occurred. During the first year after the treatment a recurrence of a fistula was observed in 30.43% of the children. In two children anaphylactic shock was observed during injection of infliximab. The remaining children tolerated the drug well. CONCLUSIONS The treatment with infliximab was effective in the majority of fistulazing Crohn's disease and caused the closure of perianal fistula which improved quality of life.
Collapse
Affiliation(s)
- Barbara M Iwańczak
- 2nd Department and Clinic of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland
| | - Józef Ryżko
- Children's Memorial Health Institute, Warszawa, Poland
| | | | - Małgorzata Sładek
- Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University School of Medicine, Kraków, Poland
| | - Agata Wasilewska
- Department of Pediatrics, Gastroenterology and Nutrition, Jagiellonian University School of Medicine, Kraków, Poland
| | - Mariusz Szczepanik
- Department of Pediatric Gastroenterology and Metabolic Disorders, Poznan Univeristy of Medical Sciences, Poland
| | - Edyta Sienkiewicz
- Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Poland
| | - Anna Szaflarska-Popławska
- Department of Pediatrics, Allergology and Gastroenterology, L. Rydygiera Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
| | - Sabina Więcek
- Department of Pediatrics, Medical University of Silesia, Gastroenterology Unit, Upper-Silesian Child Health Care Center in Katowice, Poland
| | - Jarosław Kwiecień
- Gastroenterology Division, Department of Pediatrics, Medical University of Silesia, Zabrze, Poland
| | | | | |
Collapse
|
4
|
Iwańczak B, Ryzko J, Kierkuś J, Jankowski P, Sładek M, Wasilewska A, Landowski P, Szczepanik M, Krzesiek E, Sienkiewicz E, Szaflarska-Popławska A, Wiecek S, Kwiecien J, Kacperska M, Korczowski B, Maślana J. [Biological treatment of inflammatory bowel diseases in children in the years 2004-2013 in Poland]. Pol Merkur Lekarski 2014; 36:311-315. [PMID: 24964507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
UNLABELLED In the last years an increase in Crohn's disease morbidity in children is observed together with constant morbidity of ulcerative colitis. The course of these diseases is severe, younger children are affected and the diseases are resistant to conventional treatment. Biological drugs are a chance for a longer remission and healing of the intestinal mucosa. OBJECTIVE OF THE WORK: Assessment of the use of biological drugs in treatment of inflammatory bowel disease in Poland was the objective of the work. MATERIAL AND METHODS Gastroenterological centers treating inflammatory bowel disease during the years 2004-2013 were invited to a questionnaire retrospective study. RESULTS The questionnaires of biological treatment of Crohn's disease and ulcerative colitis in children were received from 12 centers. In the years 2004-2013 the number of children aged 4 months to 18 years with Crohn's disease treated with biological drugs was 424. In the years 2004-2008--69 children were treated with infliximab and in the years 2009-2013--299 children, which was a four-fold increase. 56 children were treated with adalimumab in the years 2008-2013. In the years 2005-2013--72 children with ulcerative colitis were treated with infliximab and 11 with adalimumab. The age of the children ranged from 2 years to 18 years. The higher number of children treated was in the years 2009-2013: 59 with infliximab and 10 with adalimumab. CONCLUSIONS In the last decade a significant increase on the number of children with Crohn's disease and ulcerative colitis treated with biological drugs was observed. It is connected not only to greater morbidity but above all to the introduction of a treatment program by the National Health Insurance Fund for children with Crohn's disease. There is an expectation that the introduction of biological treatment in inflammatory bowel disease will prolong clinical and endoscopic remission and diminish the number of surgeries.
Collapse
|
5
|
Cwiklińska M, Czogała M, Balwierz W, Hnatko-Kołacz M, Moryl-Bujakowska A, Malinowska I, Sładek M, Wieczorek M, Fyderek K, Matysiak M, Rygielska M, Sierhej I. [Hemophagocytic syndrome in children with different underlying conditions]. Przegl Lek 2010; 67:430-435. [PMID: 21344776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Hemophagocytic syndrome (HS) is a life-threatening condition of hyperinflammation. Main symptoms are: prolonged fever, cytopenia, hepatosplenomegaly, hemophagocytosis, hyperferritinemia, hypertriglyceridemia and hypofibrinogenemia. Primary genetic form and secondary HS associated with infections, malignancies or autoimmune disorders can be distinguished. Untreated HS in most cases leads to death. We analyzed retrospectively 7 cases of HS in children (3 girls, 4 boys; aged 10 days -14 years) treated in 3 different pediatric centers from 2004 to 2009. In 3 cases HS was associated with infections (EBV, CMV, Bacillus Calmette Guerin - BCG), in 1 child with non-Hodgkin anaplastic large cell lymphoma (ALCL), in 1 patients probably with side effect of antiepileptic drug. In 2 cases cause of HS remained unknown. Fever, hepatomegaly, pan- or bicytopenia and hyperferritinemia were present in all children. In addition, splenomegaly was noted in 6 cases, hemophagocytosis in 6 children, impaired function or decreased number of NK cells in 4 cases, hypofibrino-genemia in 5 and hypotriglyceridemia in 4 patients. Among other symptoms and signs we observed: lymphadenopathy, hepatic failure, oedema, rash, neurological symptoms, increased level of LDH and inflammatory markers. In one child acute pancreatitis occurred. Among others, antibiotics, antiviral and immunosuppressive drugs were used in therapy. HLH-2004 protocol was applied in 4 cases. Patient with ALCL was treated with chemotherapy and allogeneic stem cell transplantation. Four patients are alive, 2 died because of HS, child with ALCL died because of generalized infection in peritrans-plantation period. In case of prolonged fever, splenomegaly and cytopenia diagnosis of HS should be considered. Following tests are recommended: complete blood count, ferritin, triglycerides, fibrinogen, bone marrow aspiration and NK cell assessment. Patients should be also screened for infections and malignancies. Early diagnosis of HS and underlying condition is crucial to start lifesaving therapy.
Collapse
Affiliation(s)
- Magdalena Cwiklińska
- Klinika Onkologii i Hematologii Dzieciecej, Polsko-Amerykański Instytut Pediatrii, UJ CM w Krakowie.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Fyderek K, Strus M, Kowalska-Duplaga K, Gosiewski T, Wędrychowicz A, Jedynak-Wąsowicz U, Sładek M, Pieczarkowski S, Adamski P, Kochan P, Heczko PB. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol 2009; 15:5287-94. [PMID: 19908336 PMCID: PMC2776855 DOI: 10.3748/wjg.15.5287] [Citation(s) in RCA: 102] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To assess the mucosa-associated bacterial microflora and mucus layer in adolescents with inflammatory bowel disease (IBD).
METHODS: Sixty-one adolescents (mean age 15 years, SD ± 4.13) were included in the study. Intestinal biopsies from inflamed and non-inflamed mucosa of IBD patients and from controls with functional abdominal pain were cultured under aerobic and anaerobic conditions. The number of microbes belonging to the same group was calculated per weight of collected tissue. The mucus thickness in frozen samples was measured under a fluorescent microscope.
RESULTS: The ratios of different bacterial groups in inflamed and non-inflamed mucosa of IBD patients and controls were specific for particular diseases. Streptococcus spp. were predominant in the inflamed mucosa of Crohn’s disease (CD) patients (80% of all bacteria), and Lactobacillus spp. were predominant in ulcerative colitis patients (90%). The differences were statistically significant (P = 0.01-0.001). Lower number of bifidobacteria was observed in the whole IBD group. A relation was also found between clinical and endoscopic severity and decreased numbers of Lactobacillus and, to a lesser extent, of Streptococcus in biopsies from CD patients. The mucus layer in the inflamed sites was significantly thinner as compared to controls (P = 0.0033) and to non-inflamed areas in IBD patients (P = 0.031).
CONCLUSION: The significantly thinner mucosa of IBD patients showed a predominance of some aerobes specific for particular diseases, their numbers decreased in relation to higher clinical and endoscopic activity of the disease.
Collapse
|
7
|
Sładek M, Jedynak-Wasowicz U, Wedrychowicz A, Kowalska-Duplaga K, Pieczarkowski S, Fyderek K. [The low prevalence of Helicobacter pylori gastritis in newly diagnosed inflammatory bowel disease children and adolescent]. Przegl Lek 2007; 64 Suppl 3:65-67. [PMID: 18431918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Data concerning prevalence rate of Helicobacter pylori gastritis in inflammatory bowel disease (IBD) patients is conflicting. We had studied the prevalence of Hp gastritis in newly diagnosed inflammatory bowel disease children before any pharmacological treatment was introduced. Ninety four consecutive children with inflammatory bowel diseased were enrolled into study, mean age 12.9 +/- 3.75 years, including 50 with Crohn's Disease (CD) and 44 with ulcerative colitis (UC). One hundred and four patients (mean age 13.6 +/- 4.2 year) referred for diagnostic evaluation because of recurrent abdominal pain, matched for age, sex and socioeconomic status served as a control. The results revealed a highly statistically lower prevalence of Hp gastritis in children with IBD as compared with controls (9.6% vs. 38.4%, p < 0.0001). Significantly more often Hp gastritis occurred in CD than UC patients. There was no statistical difference in mean age of IBD onset between Hp gastritis positive and negative groups (14.3 +/- 3.75 vs. 13.6 +/- 4.3 yr) was found. Our results show that in newly diagnosed IBD children, Hp gastritis is not unusual, but the prevalence rate is significantly lower comparing to the control group. The low Hp gastritis rate is not related to medical treatment, since the patients were studied before any was introduced.
Collapse
Affiliation(s)
- Małgorzata Sładek
- Klinika Pediatrii, Gastroenterologii i Zywienia, Uniwersytetu Jagiellońskiego, Collegium Medicum w Krakowie
| | | | | | | | | | | |
Collapse
|
8
|
Jarzab A, Fyderek K, Pieczarkowski S, Sładek M. [Myoelectrical activity of the stomach in children with gastroesophageal reflux]. Folia Med Cracov 2003; 44:71-8. [PMID: 15232889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
Aim of the study was analysis of the gastric myoelectrical activity changes recorded by cutaneous electrogastrography in children with gastroesophageal reflux. We analyzed cutaneous electrogastrograms (EGG) of 103 children also underwent 24-hours intraesophageal pH probe. We divided children into 2 groups basing on pH fraction time below 4 (FT): Reflux group (FT > 4%) and control group (FT < 4%). The Reflux group was formed of 54 children (27 girls and 27 boys) aged 3-17 years (mean 10.9), the control group consisted of 49 children (24 girls and 25 boys) aged 3-18 years (mean 11.4). Then we divided the Reflux group into two subgroups: "N"--with nocturnal episodes of gastroesophageal reflux--29 children (14 boys and 15 girls), "D"--with no reflux episodes during the nightime--25 children (12 girls and 13 boys). We analyzed the following pre- and postprandial EGG parameters: percentage of bradygastria, normogastria and tachygastria, total percentage of dysryhthmias, dominant frequency (PDF), dominant power (PDP), post/preprandial power ratio (PR), dominant frequency instability coefficient (DFIC). In the Reflux N group PDP was 10.24 mV2 preprandially and 17.34 mV2 after meal; in the control group PDP was 49.83 and 104.34 mV2 respectively (the differences between groups were statistically significant in both fasting and fed states: p < 0.02). In the Reflux D group comparing to the controls we found less percentage of postprandial bradygastria (p < 0.05). The other EGG parameters were no statistically different. EGG analysis suggests a different pathomechanism of gastroesophageal reflux episodes in the patients with nocturnal reflux episodes.
Collapse
Affiliation(s)
- Anna Jarzab
- Klinika Pediatrii, Gastroenterdologii i Zywienia Polsko-Amerykańskiego Instytutu Pediatrii ul. Wielicka 265, 30-663 Kraków.
| | | | | | | |
Collapse
|